GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » Tax Expense

OrbusNeich Medical Group Holdings (HKSE:06929) Tax Expense : HK$20 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OrbusNeich Medical Group Holdings Tax Expense?

OrbusNeich Medical Group Holdings's tax expense for the months ended in Jun. 2024 was HK$19 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$20 Mil.


OrbusNeich Medical Group Holdings Tax Expense Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings Tax Expense Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Expense
Get a 7-Day Free Trial 1.43 24.38 25.69 35.57 19.90

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.83 22.29 13.35 18.84 1.15

OrbusNeich Medical Group Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OrbusNeich Medical Group Holdings  (HKSE:06929) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


OrbusNeich Medical Group Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


OrbusNeich Medical Group Holdings Business Description

Traded in Other Exchanges
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Executives
Harmony Tree Limited 2101 Beneficial owner
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Suzhou Red Earth Yeju Investment Ltd. 2101 Beneficial owner
Chien David 2201 Interest of corporation controlled by you
Lau Kwai Ching Denise 2201 Interest of corporation controlled by you
Shen Chuang Tou Zhi Zao Ye Zhuan Xing Sheng Ji Xin Cai Liao Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Shen Chuang Tou Hong Tu Si Mu Gu Quan Tou Zi Ji Jin Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Hong Tu Ye Ju Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you

OrbusNeich Medical Group Holdings Headlines

No Headlines